Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?
|
|
- Miles Small
- 5 years ago
- Views:
Transcription
1 Molecular Genetics and Metabolism 86 (2005) S22 S26 Minireview Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now? Christineh N. Sarkissian a,, Alejandra Gámez b a Department of Biology, Human Genetics, and Pediatrics, McGill University, Debelle Laboratory, Montreal Children s Hospital Research Institute, 2300 Tupper Street, A-717, Montreal, QC, Canada H3H 1P3 b Department of Molecular Biology, The Scripps Research Institute, North Torrey Pines Road, La Jolla, CA 92037, USA Received 3 May 2005; received in revised form 20 June 2005; accepted 24 June 2005 Available online 13 September 2005 Abstract Phenylketonuria (PKU) is an autosomal recessive genetic disorder in which mutations in the phenylalanine-4-hydroxylase (PAH) gene result in an inactive enzyme (PAH, EC ). The evect is an inability to metabolize phenylalanine (Phe), translating into elevated levels of Phe in the bloodstream (hyperphenylalaninemia). If therapy is not implemented at birth, mental retardation can occur. PKU patients respond to treatment with a low-phenylalanine diet, but compliance with the diet is diycult, therefore the development of alternative treatments is desirable. Enzyme substitution therapy with a recombinant phenylalanine ammonia lyase (PAL) is currently being explored. This enzyme converts Phe to the harmless metabolites, trans-cinnamic acid and trace ammonia. Taken orally and when non-absorbable and protected, PAL lowers plasma Phe in mutant hyperphenylalaninemic mouse models. Subcutaneous administration of PAL results in more substantial lowering of plasma and signiwcant reduction in brain Phe levels, however the metabolic evect is not sustained following repeated injections due to an immune response. We have chemically modiwed PAL by pegylation to produce a protected form of PAL that possesses better speciwc activity, prolonged half-life, and reduced immunogencity in vivo. Subcutaneous administration of pegylated molecules to PKU mice has the desired metabolic response (prolonged reduction in blood Phe levels) with greatly attenuated immunogenicity Elsevier Inc. All rights reserved. Keywords: Phenylketonuria; Metabolic disease; Enzyme replacement therapy; Phenylalanine ammonia lyase; Phenylalanine hydroxylase The hyperphenylalaninemias (HPA) are multifactorial metabolic disorders (OMIM ) due primarily to mutations in the gene for phenylalanine hydroxylase (EC ). Approximately 500 identiwed mutations in the phenylalanine hydroxylase gene (PAH) lead to a defective PAH enzyme that impairs the disposal of the surplus phenylalanine (Phe) from normal diet. In excess, Phe itself is the neurotoxic molecule [1 3], however it is also an essential nutrient and in addition to its requirement for protein synthesis, it serves as a precursor for tyrosine (Tyr) and its derivatives. In the absence of Phe, Tyr becomes an * Corresponding author. Fax: address: christineh.sarkissian@mail.mcgill.ca (C.N. Sarkissian). essential amino acid, therefore, the treatment of HPA requires the balanced reduction of systemic Phe concentration without excessive depletion (restoring euphenylalaninemia) and satisfactory Tyr provision [1,2]. An artiwcial diet to reduce Phe intake became available in the mid-1950s [4 6]. It was uniformly accepted by the late 1960s [1,2] and was a success due to a population-screening test [7] that identiwes new-born patients and allowed treatment to begin prior to the onset of neurological damage. PKU therapy is one of the Wrst evective treatments of a genetic disease. The treatment regimen today is not much diverent. The diet products have been rewned [8 11] but the mode remains the same. It involves the careful regulation of dietary L-phenylalanine intake to <500 mg/day, suycient /$ - see front matter 2005 Elsevier Inc. All rights reserved. doi: /j.ymgme
2 C.N. Sarkissian, A. Gámez / Molecular Genetics and Metabolism 86 (2005) S22 S26 S23 to support protein synthesis while preventing excess accumulation of Phe in the free pool. These are the present standards, and the current guidelines [12,13] advise treatment to restore blood phenylalanine to levels as near normal as possible, as early as possible, for as long as possible, and for a lifetime in some patients. A low-phe diet can prevent cognitive impairment, but it is a diycult option for adolescents and adults. Multiple challenges exist: although much improved, the lowphenylalanine products continue to have unsatisfactory organoleptic properties, making long-term full compliance very laborious and requiring a great deal of social support [13 15]; pregnancies (maternal PKU) are another concern, because elevated Phe levels in the fetus are teratogenic [16]; furthermore, the diet has known dewciencies of several nutrients, all of which can be detrimental to brain development [17 19]; Wnally, a shift in homeostasis, causing protein catabolism, will result in increased blood Phe levels [20]. An alternative to dietary treatment is desirable because the current therapy incurs high personal costs to avected individuals and families, and because the normal culture of nutrition is greatly distorted. Although for the infant and young child, this aspect may be less important, for the teenage years and onward a common consequence is social isolation. With the recommendations [12,13] for dietary therapy, possibly for life, and for reintroduction of diet during conception and pregnancy for the avected woman, a change in the therapeutic mode is coveted. Alternative forms of therapy are now being explored. Somatic gene therapy by therapeutic liver repopulation has some promises, but continues at the experimental stage [21,22]. Liver transplantation will correct the metabolic phenotype but it is not a clinical option for all but the rarest of patients [23]. Large neutral amino acid supplementation to compete with Phe for transport across the blood brain barrier will help reduce brain Phe levels in adults who have PKU, but this treatment is still controversial, and recommended only for non-compliant adults who have diyculty following their diet [24,25]. The current promising potential therapy for some patients harbouring missense PAH mutations is tetrahydrobiopterin (BH 4 ) PAH-cofactor administration. The combination of milder HPA-inducing alleles found in the patient s genotype inxuences the degree of a patient s BH 4 responsiveness [26 29]. BH 4 supplementation therapy will potentially address the treatment needs of part of the hyperphenylalaninemic population; however patients with the more severe forms of classical PKU and some with non-pku HPA do not respond to BH 4 treatment. These non-responders could benewt most from enzyme therapy, which is currently under pre-clinical development. Unlike BH 4 treatment, it is not dependent on the PAH genotype. Enzyme therapy for PKU can be done either by replacement with phenylalanine hydroxylase or by substitution with phenylalanine ammonia lyase enzyme (PAL, EC ), a foreign protein involved in Phe degradation. Both approaches can reduce the elevated Phe by acting as proxy to the dewcient PAH enzyme of the PKU patient. Replacement of the native PAH enzyme (the primary choice) presents a number of challenges: PAH is inherently unstable, making large-scale isolation and puriwcation of the enzyme an ambitious task; its complex activity and cofactor (BH 4 ) requirement in addition to the inherent protease sensitivity and potential immunogenicity in a person lacking the functional enzyme further complicate the venture. Enzyme replacement therapy with PAH requires the intact multienzyme complex for catalytic hydroxylating activity [1,2]. To make it therapeutically viable, modiwcation of the PAH molecule is required. Truncated forms of PAH have been constructed in an attempt to stabilize and increase catalytic activity [30]. In addition, protection of the enzyme against immune response has been achieved by polyethylene glycol (PEG) chemical conjugation (pegylation) of the protein [31]. Human and various bacterial PAH have been successfully pegylated with retention of full or near-full and in some cases augmented catalytic activity; the modiwed molecules are also more stable than their non-derivatized PAH counterparts [32]. The growing number of pegylated enzyme therapeutics, displaying improved pharmacokinetic and pharmacodynamic prowles that are currently approved by the Food and Drug Administration (FDA) [31,33] tells a promising story. Exploring pegylated-pah as a long-term injectable molecule for PKU is ongoing, but given the drawbacks of the enzyme, its viability as a therapeutic remains debatable [32]. PAL is a potential substitute for the native PAH protein. In fungal cells, PAL has a strictly catabolic role [34], while in plants, it is a key biosynthetic enzyme catalyzing the Wrst reaction in the synthesis of a variety of polyphenyl compounds [35 37]. PAL is an autocatalytic protein responsible for the non-oxidative deamination of L- phenylalanine to form trans-cinnamic acid and ammonia [38 40]. trans-cinnamate has no embryotoxic evects in laboratory animals [41] and is excreted as hippurate in urine [42] along with small amounts of cinnamic and benzoic acids [39]. The»3g trans-cinnamic acid, that would be generated daily with complete dietary Phe conversion by PAL, is predicted to be harmless to both PKU and normal individuals; the ammonia formed would be metabolically insigniwcant [39,43]. The optimal ph and temperature for PAL activity is 8.5 at 30 C, a feature compatible with an enteral route for PAL therapy [44]; but the enzyme will normally experience proteolytic degradation in the intestinal lumen [45] unless it is protected [46]. If it were injected
3 S24 C.N. Sarkissian, A. Gámez / Molecular Genetics and Metabolism 86 (2005) S22 S26 parenterally, as another option, it would be immunogenic [47] (a reaction already reported when animals have been injected with PAL [43,48]), unless the protein is modiwed to suppress its immunogenicity [31]. Initial attempts to avoid eliciting an immune response used an extracorporeal multitubular enzyme reactor with immobilized PAL to reduce plasma Phe levels signiwcantly without the enzyme entering the circulation [49]. However this is not a viable long-term option, and for treatment, the original proposed route for protected therapeutic PAL administration was oral. This approach capitalized on PAL depleting the Phe pool as it passed through the intestine, while evading problems with immune response associated with accumulation of synthetic injectable drugs [50 54]. Various formulations and mechanisms, to prevent protease inactivation, have been tested. Measures to immobilize PAL [51] have shown signiwcant plasma Phe reduction [55]. Preliminary studies in human PKU patients showed analogous responses after the administration of PAL in enteric-coated gelatin capsules [43]. Entrapment of enzyme in silk Wbroin [56] and in adenocarcinoma cell line Caco-2 [57] were other proposals. These studies were not continued because at the time PAL was not available in suycient amounts at an acceptable cost. Treatment with PAL, puriwed from a natural source, has a predicted daily cost comparable to the approximated annual expense per patient of the dietary therapy. PAL enzyme substitution therapy became a viable option only when cloning technology allowed the production of virtually limitless quantities of recombinant PAL (the gene was acquired from yeast Rhodosporidium toruloides). Access to the orthologous mouse models of human PKU and HPA [58 60] made pre-clinical in vivo studies possible. Our earlier work [61] used mutant ENU mouse orthologues of non-pku HPA and PKU to demonstrate proofs of pharmacological and physiological principles in the eycacy of the recombinant PAL depleting systemic Phe levels. The Wrst was achieved by intra-peritoneal injection of recombinant PAL, which acted in vivo to lower ambient blood Phe levels. The evect persisted over 24 h following treatment, with plasma Phe levels markedly lower than those measured at zero time prior to the administration of the enzyme. The second was demonstrated when recombinant PAL administered orally and protected from degradation by intestinal digestion, actively depleting phenylalanine. Two diverent systems were applied. First recombinant PAL expressed in a non-pathogenic Escherichia coli organism provided a protective environment for the enzyme from the action of digestive proteases, which were unable to penetrate the cells. The free Phe, in the intestinal lumen, was transported through the bacterial membrane and converted by the recombinant PAL to trans-cinnamic acid, reducing Phe levels by 44% within 2 h post-administration. The second system capitalized on recombinant PAL delivery in solution with aprotinin protease inhibitor. This mixture, placed in the intestinal lumen, again acted in vivo evectively depleting the systemic phenylalanine levels, this time by 54% within 2 h post-administration. Recombinant PAL has the desired evect on elevated plasma phenylalanine in the PKU phenotype. Moreover brain Phe levels are improved by parenteral (injectable) recombinant PAL administration [62]. However, parenteral use of native recombinant PAL produces an immune response and while an enteral route for PAL therapy is still the most desirable form of enzyme substitution therapy, the current protease-protected variants require a long contact time between the enzyme formulations and substrate, during passage through small and large intestine. In addition, low speciwc activity means that a large amount of the recombinant PAL formulations is required to lower plasma phenylalanine in PKU. All these factors make oral therapy a continued challenge. Enzyme replacement therapy has become a signiwcant approach to treatment of inborn errors of metabolism [33]; thus to treat PKU with an injectable enzyme would not be an unexplored therapeutic paradigm in genetic medicine. Current knowledge about the crystal structures of PAH [30,63 66] and of PAL [67] will allow the application of structure-based molecular engineering to optimize the recombinant PAL protein architecture. The desired product here would be an injectable recombinant PAL therapeutic, with satisfactory immune tolerance in vivo. Our work now focuses on chemical modiwcations of the recombinant PAL molecule, to develop a protected form of the enzyme that retains satisfactory speciwc activity against phenylalanine substrate and yet with suppressed immunogenicity. A series of linear and branched polyethylene glycols chemically conjugated to recombinant PAL have set these wheels in motion [68]. These pegylated recombinant PAL conjugates reduce plasma Phe levels evectively and they mask immunogenicity in vivo after repeated challenge [68]. The new procedures for synthesis of modiwed recombinant PAL exclude unmodiwed (native) recombinant PAL from the Wnal product [68]. Our Wndings so far constitute a new set of proofs-of-principle for the use of parenteral recombinant PAL enzyme substitution in the treatment of PKU under the conditions of the new guidelines [12,13]. Acknowledgments The authors acknowledge their mentors Drs. Charles R. Scriver and Raymond C. Stevens for their vision, endless enthusiasm, and their invaluable advice in the development of PAL therapy for PKU treat-
4 C.N. Sarkissian, A. Gámez / Molecular Genetics and Metabolism 86 (2005) S22 S26 S25 ment. We are also grateful to our colleagues in this project who made the work possible, Dr. Lin Wang, Mélanie Hutubise, and Mary Straub. This work was supported in part by the Medical Research Council (Canada), the Canadian Genetic Diseases Network (Networks of Centers of Excellence), IBEX Technologies, BioMarin Pharmaceutical Inc., the National PKU Society (UK), the Garrod Association (Canada), the Michaux Family, and the Piziali Family Foundation (USA). References [1] C.R. Scriver, S. Kaufman, Hyperphenylalaninemia: phenylalanine hydroxylase dewciency, in: The Metabolic and Molecular Bases of Inherited Disease, McGraw Hill, New York, [2] J. Donlon, H. Levy, C.R. Scriver, Hyperphenylalaninemia: phenylalanine hydroxylase dewciency, in: The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York, 2004, Chapter 77. [3] C.N. Sarkissian, C.R. Scriver, O.A. Mamer, Measurement of phenyllactate, phenylacetate, and phenylpyruvate by negative ion chemical ionization-gas chromatography/mass spectrometry in brain of mouse genetic models of phenylketonuria and non-phenylketonuria hyperphenylalaninemia, Anal. Biochem. 280 (2000) [4] H. Bickel, J. Gerrard, E.M. Hickmans, The InXuence of phenylalanine intake on the chemistry and behaviour of a phenylketonuric child, Acta Paediat. 43 (1954) [5] L.I. Woolf, R. GriYths, A. MoncrieV, Treatment of phenylketonuria with a diet low in phenylalanine, Br. Med. J (1955) [6] M.D. Armstrong, F.H. Tyler, Studies on phenylketonuria. I. Restriction phenylalanine intake in phenylketonuria, J. Clin. Invest. 34 (1955) [7] R. Guthrie, A. Susi, A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants, Pediatrics 32 (1963) [8] N.R. Buist, A.P. Prince, K.L. Huntington, J.M. Tuerck, D.D. Waggoner, A new amino acid mixture permits new approaches to the treatment of phenylketonuria, Acta Paediatr. Suppl. 407 (1994) [9] H.H. Kecskemethy, D. Lobbregt, H.L. Levy, The use of gelatin capsules for ingestion of formula in dietary treatment of maternal phenylketonuria, J. Inherit. Metab. Dis. 16 (1993) [10] B.E. Hainline, S.C. Ems-McClung, Gamma zein: a new high protein Phe-free diet supplement, Natl. PKU News 10 (1999) 2. [11] D. Ayares, A. D Acy, Alpha-lac: another diet supplement on the horizon, Natl. PKU News 10 (1999) 2. [12] Medical Research Council (UK), Phenylketonuria due to phenylalanine hydroxylase dewciency: an unfolding story, BMJ 306 (1993) [13] F. Cockburn, B.E. Barwell, D.P. Brenton, J. Chapple, B. Clark, G. Curzon, D.C. Davidson, A.J. Heeley, S.C. Laing, I.A.F., et al., Lister-Cheese, Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria, Arch. Dis. Child. 68 (1993) [14] F. Cockburn, B.J. Clark, Recommendations for protein and amino acid intake in phenylketonuric patients, Eur. J. Pediatr. 155 (1996) S125 S129. [15] H.L. Levy, Phenylketonuria: old disease, new approach to treatment [comment], Proc. Natl. Acad. Sci. USA 96 (1999) [16] R. Lenke, H. Levy, Maternal phenylketonuria results of dietary therapy, Am. J. Obstet. Gynecol. 142 (1982) [17] I. Smith, Treatment of phenylalanine hydroxylase dewciency, Acta Paediatr. (Suppl. 407) (1994) [18] F. Cockburn, B.J. Clark, E.A. Caine, A. Harvie, J. Farquharson, E.C. Jamieson, P. Robinson, R.W. Logan, Fatty acids in the stability of neuronal membrane: relevance to PKU, Internat. Pediatr. 11 (1996) [19] E. Riva, C. Agostoni, G. Biasucci, S. Trojan, D. Luotti, L. Fiori, M. Giovannini, Early breastfeeding is linked to higher intelligence quotient scores in dietary treated phenylketonuric children, Acta Paediatr. 85 (1996) [20] R.W. Wannemacher Jr., A.S. Klainer, R.E. Dinterman, W.R. Beisel, The signiwcance and mechanism of an increased serum phenylalanine tyrosine ratio during infection, Am. J. Clin. Nutr. 29 (1976) [21] Z. Ding, C.O. Harding, B. Thony, State-of-the-art 2003 on PKU gene therapy, Mol. Genet. Metab. 81 (2004) 3 8. [22] C.O. Harding, Recent advances in cell and gene therapy for PKU, Natl. PKU News 16 (2004) 1 5. [23] P. Vajro, P. Strisciuglio, D. Houssin, G. Huault, J. Laurent, F. Alvarez, O. Bernard, Correction of phenylketonuria after liver transplantation in a child with cirrhosis, N. Engl. J. Med. 329 (1993) 363. [24] R.A. Moats, R. Koch, K. Moseley, P. Guldberg, F. Guttler, R.G. Boles, M.D. Nelson Jr., Brain phenylalanine concentration in the management of adults with phenylketonuria, J. Inherit. Metab. Dis. 23 (2000) [25] R. Koch, K.D. Moseley, S. Yano, M. Nelson Jr., R.A. Moats, Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment, Mol. Genet. Metab. 79 (2003) [26] R. Matalon, R. Koch, K. Michals-Matalon, K. Moseley, S. Surendran, S. Tyring, H. Erlandsen, A. Gámez, R.C. Stevens, A. Romstad, L.B. Moller, F. Guttler, Biopterin responsive phenylalanine hydroxylase dewciency, Genet. Med. 6 (2004) [27] C. Bernegger, N. Blau, High frequency of tetrahydrobiopterinresponsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002, Mol. Genet. Metab. 77 (2002) [28] A. Muntau, W. Roschinger, M. Habich, H. Demmelmair, B. HoVmann, C. SommerhoV, A. Roscher, Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria, N. Engl. J. Med. 347 (2002) [29] N. Blau, H. Erlandsen, The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase dewciency, Mol. Genet. Metab. 82 (2004) [30] H. Erlandsen, M.G. Patch, A. Gamez, M. Straub, R.C. Stevens, Structural studies on phenylalanine hydroxylase and implications toward understanding and treating phenylketonuria, Pediatrics 112 (2003) [31] W. Kim, H. Erlandsen, S. Surendran, R.C. Stevens, A. Gámez, K. Michals-Matalon, S.K. Tyring, R. Matalon, Trends in enzyme therapy for phenylketonuria, Mol. Ther. 10 (2004) [32] A. Gámez, L. Wang, M. Straub, M.G. Patch, R.C. Stevens, Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase, Mol. Ther. 9 (2004) [33] J.M. Harris, R.B. Chess, EVect of pegylation on pharmaceuticals, Nat. Rev. Drug Discov. 2 (2003) [34] J.G. Anson, H.J. Gilbert, J.D. Oram, N.P. Minton, Complete nucleotide sequence of the Rhodosporidium toruloides gene coding for phenylalanine ammonia-lyase, Gene 58 (1987) [35] C. Appert, E. Logemann, K. Hahlbrock, J. Schmid, N. Amrhein, Structural and catalytic properties of the four phenylalanine ammonia-lyase isoenzymes from parsley (Petroselinum crispum Nym), Eur. J. Biochem. 225 (1994) [36] Y. Tanaka, M. Matsuoka, N. Yamanoto, Y. Ohashi, Y. Kano- Murakami, Y. Ozeki, Structure and characterization of a cdna clone for phenylalanine ammonia-lyase from cut-injured roots of sweet potato, Plant Physiol. 90 (1989)
5 S26 C.N. Sarkissian, A. Gámez / Molecular Genetics and Metabolism 86 (2005) S22 S26 [37] L.A. Wanner, G. Li, D. Ware, I.E. Somssich, K.R. Davis, The phenylalanine ammonia-lyase gene family in Arabidopsis thaliana, Plant Mol. Biol. 27 (1995) [38] D.S. Hodgins, Yeast phenylalanine ammonia-lyase. PuriWcation, properties, and the identiwcation of catalytically essential dehydroalanine, J. Biol. Chem. 10 (1971) [39] J.A. Hoskins, S.B. Holliday, A.M. Greenway, The metabolism of cinnamic acid by healthy and phenylketonuric adults: a kinetic study, Biomed. Mass Spectrom. 11 (1984) [40] J.F. Kane, M.J. Fiske, Regulation of phenylalanine ammonia lyase in Rhodotorula glutinis, J. Bacteriol. 161 (1985) [41] J.A. Hoskins, J. Gray, Phenylalanine ammonia lyase in the management of phenylketonuria: the relationship between ingested cinnamate and urinary hippurate in humans, Res. Commun. Chem. Pathol. Pharmacol. 35 (1982) [42] J. Snapper, T.F. Chiang, T.Y. Chiang, Cinnamic acid metabolism in man, Proc. Soc. Exp. Biol. Med. 44 (1940) [43] J.A. Hoskins, G. Jack, H.E. Wade, R.J. Peiris, E.C. Wright, D.J. Starr, J. Stern, Enzymatic control of phenylalanine intake in phenylketonuria, Lancet 1 (1980) [44] K. Ogata, K. Uchiyama, H. Yamada, T. Tochikura, Metabolism of aromatic amino acid in microorganisms. Part ii. Properties of phenylalanine ammonia-lyase of Rhodotorula, Agric. Biol. Chem. 31 (1967) [45] H.J. Gilbert, G.W. Jack, The evect of proteinases on phenylalanine ammonia-lyase from the yeast rhodotorula glutinis, Biochem. J. 199 (1981) [46] H. Gilbert, M. Tully, Protection of phenylalanine ammonia-lyase from proteolytic attack, Biochem. Biophys. Res. Commun. 131 (1985) [47] K.J. Wieder, N.C. Palczuk, T. van Es, F.F. Davis, Some properties of polyethylene glycol:phenylalanine ammonia-lyase adducts, J. Biol. Chem. 254 (1979) [48] R.R. Fritz, D.S. Hodgins, C.W. Abell, Phenylalanine ammonialyase. Induction and puriwcation from yeast and clearance in mammals, J. Biol. Chem. 251 (1976) [49] C.M. Ambrus, S. Anthone, C. Horvath, K. Kalghatgi, A.S. Lele, G. Eapen, J.L. Ambrus, A.J. Ryan, P. Li, Extracorporeal enzyme reactors for depletion of phenylalanine in phenylketonuria, Ann. Intern. Med. 106 (1987) [50] L. Bourget, T.M. Chang, Phenylalanine ammonia-lyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model, Biochim. Biophys. Acta 883 (1986) [51] L. Bourget, T.M. Chang, Phenylalanine ammonia-lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria, FEBS Lett. 180 (1985) 5 8. [52] T.M. Chang, S. Prakash, Therapeutic uses of microencapsulated genetically engineered cells, Mol. Med. Today 4 (1998) [53] T.M. Chang, ArtiWcial cells with emphasis on bioencapsulation in biotechnology, Biotechnol. Annu. Rev. 1 (1995) [54] W. Wang, Oral protein drug delivery, J. Drug Target 4 (1996) [55] S. Safos, T.M. Chang, Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report, Artif. Cells Blood Substit. Immobil. Biotechnol. 23 (1995) [56] S. Inoue, Y. Matsunaga, H. Iwane, M. Sotomura, T. Nose, Entrapment of phenylalanine ammonia-lyase in silk Wbroin for protection from proteolytic attack, Biochem. Biophys. Res. Commun. 141 (1986) [57] L. Hovgaard, S.W. Jorgensen, P. Eigtved, S. Frokjaer, H. Brondsted, Drug delivery studies in Caco-2 monolayers. VI. studies of enzyme substitution therapy for phenylketonuria a new application of Caco-2 monolayers, Int. J. Pharm. 161 (1998) [58] A. Shedlovsky, J. McDonald, D. Symula, W. Dove, Mouse models of human phenylketonuria, Genetics 134 (1993) [59] J. McDonald, V. Bode, W. Dove, A. Shedlovsky, Pah hph-5 : a mouse mutant dewcient in phenylalanine hydroxylase, Proc. Natl. Acad. Sci. USA 87 (1990) [60] C.N. Sarkissian, D.M. Boulais, J.D. McDonald, C.R. Scriver, A heteroallelic mutant mouse model: a new orthologue for human hyperphenylalaninemia, Mol. Genet. Metab. 69 (2000) [61] C.N. Sarkissian, Z. Shao, F. Blain, R. Peevers, H. Su, R. Heft, T.M. Chang, C.R. Scriver, A diverent approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase, Proc. Natl. Acad. Sci. USA 96 (1999) [62] C. Sarkissian, D. Boulais, Z. Shao, M. Pedneault, R. Heft, C. Scriver, First evidence that extra-cerebral recombinant phenylalanine ammonia lyase treatment will reduce brain phenylalanine in Phenylketonuria, Am. J. Hum. Genet. 73 (2003) 459, Abst [63] H. Erlandsen, F. Fusetti, A. Martinez, E. Hough, T. Flatmark, R.C. Stevens, Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria, Nat. Struct. Biol. 4 (1997) [64] F. Fusetti, H. Erlandsen, T. Flatmark, R. Stevens, Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria, J. Biol. Chem. 273 (1998) [65] H. Erlandsen, E. Bjorgo, T. Flatmark, R.C. Stevens, Crystal structure and site-speciwc mutagenesis of pterin-bound human phenylalanine hydroxylase, Biochemistry 39 (2000) [66] H. Erlandsen, J. Kim, M. Patch, A. Han, A. Volner, M. Abu-Omar, R. Stevens, Structural comparison of bacterial and human irondependent phenylalanine hydroxylases: similar fold, diverent stability and reaction rates, J. Mol. Biol. 320 (2002) [67] J.C. Calabrese, D.B. Jordan, A. Boodhoo, S. Sariaslani, T. Vannelli, Crystal structure of phenylalanine ammonia lyase: multiple helix dipoles implicated in catalysis, Biochemistry 43 (2004) [68] A. Gamez, C. Sarkissian, L. Wang, W. Kim, M. Straub, M. Patch, L. Chen, S. Striepeke, P. Fitzpatrick, J. Lemontt, C. O Neill, C. Scriver, R. Stevens, Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria, Mol. Ther. 11 (2005)
Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study
Molecular Genetics and Metabolism 86 (2005) S1 S5 www.elsevier.com/locate/ymgme Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study Betina Fiege
More informationTrends in Enzyme Therapy for Phenylketonuria
Trends in Enzyme Therapy for Phenylketonuria Woomi Kim, 1,2 Heidi Erlandsen, 3, * Sankar Surendran, 4 Raymond C. Stevens, 1 Alejandra Gamez, Kimberlee Michols-Matalon, Stephen K. Tyring, 5 and Reuben Matalon
More informationNew treatment options in PKU and future role of dietary treatment
New treatment options in PKU and future role of dietary treatment Michael Staudigl (physician), Katharina Dokoupil (nutritionist), Esther M. Maier (physician, head of department) Dr. von Hauner Children
More informationPhenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine
Phenylketonuria (PKU) the Biochemical Basis Biol 405 Molecular Medicine PKU a history In 1934 Følling identified a clinical condition - imbecillitas phenylpyruvica. Mental retardation associated with this
More informationThe phenylketonuria mouse model: a meeting review
Molecular Genetics and Metabolism 76 (2002) 256 261 Review The phenylketonuria mouse model: a meeting review J. David McDonald, a, * Maria Andriolo, b Francesco Calı, b Mario Mirisola, c Stefano Puglisi-Allegra,
More informationAnnual Conference. 34th. The Rendezvous Hotel Skipton, Yorkshire. Welcome to. Programme Information & Abstracts
Welcome to 34th Annual Conference 2007 Programme Information & Abstracts The Rendezvous Hotel Skipton, Yorkshire The National Society for Phenylketonuria (United Kingdom) Ltd. NSPKU, PO Box 26642, London
More informationKinetic and stability analysis of PKU mutations identiwed in BH 4 -responsive patients
Molecular Genetics and Metabolism 86 (2005) S11 S16 Minireview www.elsevier.com/locate/ymgme Kinetic and stability analysis of PKU mutations identiwed in BH 4 -responsive patients Belén Pérez a, Lourdes
More informationExcerpt from J. Mol. Biol. (2002) 320, :
Excerpt from J. Mol. Biol. (2002) 320, 1095 1108: Crystal Structure of the Ternary Complex of the Catalytic Domain of Human Phenylalanine Hydroxylase with Tetrahydrobiopterin and 3-(2-Thienyl)-L-alanine,
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 101 (2010) 110 114 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Sapropterin therapy increases
More informationNutritional factors affecting serum phenylalanine concentration during pregnancy for identical twin mothers with phenylketonuria
Nutritional factors affecting serum phenylalanine concentration during pregnancy for identical twin mothers with phenylketonuria By: C. Fox, J. Marquis, D.E. Kipp This is the accepted version of the following
More informationPhenylketonuria Jonathan Baghdadi and Evan Marlin
Phenylketonuria Jonathan Baghdadi and Evan Marlin Hyperphenylalaninemia (HPA) was first connected to certain types of mental retardation in 1934 by Asjborn Folling. Just a few years later it was understood
More informationMerck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU Below 4 Years of Age
Your Contact News Release Gangolf Schrimpf +49 6151 72-9591 Investor Relations +49 6151 72-3321 July 20, 2015 Merck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU
More information1 Cognitive, Psychological and Behavioral Assessment Based Evidence
1 Cognitive, Psychological and Behavioral Assessment Based Evidence Preface Current medical evidence has led experts on PKU to suspect that current therapy for PKU may leave individuals with an increased
More informationNot intended for UK based media. Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years of age
Your Contact News Release Bettina Frank Phone +49 6151 72-4660 Not intended for UK based media Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years
More informationPathophysiology of the Phenylketonuria
Problem 4. Pathophysiology of the Phenylketonuria Readings for this problem are found on pages: 79-82, 84, 85-6, 945-6 and 1019 of your Pathophysiology (5 th edition) textbook. (This problem was based
More informationChapter 1: What is PKU?
Chapter 1: What is PKU? A Parent's Perspective "If our child with PKU had been our first instead of our third, or if we had wanted more children after we had her, we would have done so, even knowing the
More informationPKU, a genetic disease, illustrating the principle:
PKU, a genetic disease, illustrating the principle: DNA RNA Protein What happens when a job doesn t get done? I. PKU, illustrates the relevance of chemistry to human health. PKU stands for phenylketonuria.
More informationAMERICAN ACADEMY OF PEDIATRICS. New Developments in Hyperphenylalaninemia. Committee on Nutrition
AMERICAN ACADEMY OF PEDIATRICS Committee on Nutrition New Developments in Hyperphenylalaninemia In recent years it has become apparent that hyperphenylalaninemia in newborn infants may be caused by a variety
More informationAmal Alamri. Phenylketonuria
Amal Alamri Phenylketonuria Norwegian doctor Asbjørn Følling (left) discovered phenylpyrouvica (later termed phenylketonuria) in 1934 upon discovering that ten mentally retarded patients had phenylpyruvic
More informationTherapeutic Programming of Synthetic Biotic Medicines
Therapeutic Programming of Synthetic Biotic Medicines Synthetic Biotic TM medicines to perform and deliver critical therapeutic functions to treat diseases throughout the body An Engineered E. coli Nissle
More informationA. We are constantly being tested (from birth). 1) Why? Test newborns to check for congenital health problems. 2) What does congenital mean?
M 109 Introduction I. PKU illustrates the relevance of chemistry to human health Why is chemistry important in human health? Ex.: PKU (phenylketonuria) ref. Matalon, KM Top lin Nutr 16(4):41-50 (2001)
More informationSummary comments: An essential pattern employed by all living things: DNA ö RNA ö Protein
Summary comments: An essential pattern employed by all living things: DNA ö RNA ö Protein DNA is the information storage molecule. RNA in an intermediate in information flow. Proteins do most of the jobs
More informationPhenylalanine. in cases of hyperphenylalaninemia and tetrahydrobiopterin deficiency
Evolving Methods for the Measurement of Phenylalanine A vital diagnostic marker and indicator for follow-up in cases of hyperphenylalaninemia and tetrahydrobiopterin deficiency Dr. Zoltan Lukacs Department
More informationUse of Enzyme Artificial Cells for Genetic Enzyme Defects that Increase Systemic Substrates to Toxic Levels
CHAPTER 6 Use of Enzyme Artificial Cells for Genetic Enzyme Defects that Increase Systemic Substrates to Toxic Levels 6.1. Introduction General The basic principle on the use of artificial cells containing
More informationPhenylketonuria (PKU) Structure of Phenylalanine Hydroxylase. Biol 405 Molecular Medicine
Phenylketonuria (PKU) Structure of Phenylalanine Hydroxylase Biol 405 Molecular Medicine 1998 Crystal structure of phenylalanine hydroxylase solved. The polypeptide consists of three regions: Regulatory
More informationArtificial liver in PKU. Donna Santillan, PhD University of Iowa Hospitals & Clinics Department of Obstetrics & Gynecology
Artificial liver in PKU Donna Santillan, PhD University of Iowa Hospitals & Clinics Department of Obstetrics & Gynecology Discovery of PKU Discovery of PKU Discovered in 1934 by Dr. Asbjörn Fölling Egeland
More informationINVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU
: 293-297 ISSN: 2277 4998 INVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU SHIRIN JAHANBAZI, FATEMEHKESHAVARZI* Department of Biology, Sanandaj Branch,
More informationPhenylketonuria and Its Variants
ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 7, No. 2 Copyright 1977, Institute for Clinical Science Phenylketonuria and Its Variants SEYMOUR KAUFMAN, Ph.D. and SHELDON MILSTIEN Ph.D. Laboratory of
More informationThe What, Why and How of Large Neutral Amino Acids
The What, Why and How of Large Neutral Amino Acids Kathryn Moseley, MS, RD Assistant Professor of Pediatrics USC/Keck School of Medicine LAC+USC Medical Center December 5 th, 2017 The opinions reflected
More informationPAH phenylalanine + oxidant tyrosine CH 2 +H 3 N
M 109 Introduction An essential pattern employed by all living things: DNA RNA Protein DNA is the information storage molecule. RNA is an intermediate in information flow. Proteins do most of the jobs
More informationRecent Studies of Phenylketonuria By: Jennifer Gastelum Dr. Koni Stone Copyright 2014
Recent Studies of Phenylketonuria By: Jennifer Gastelum Dr. Koni Stone Copyright 2014 Phenylketonuria (PKU) is an autosomal recessive genetic disorder that causes an accumulation of toxic metabolites in
More informationPKU, KUVAN, and Your Child Making smart choices for PKU treatment
PKU, KUVAN, and Your Child Making smart choices for PKU treatment An educational brochure brought to you by BioMarin Pharmaceutical Inc. + = Low Low- diet Indication KUVAN (sapropterin dihydrochloride)
More informationChapter 9. Biotransformation
Chapter 9 Biotransformation Biotransformation The term biotransformation is the sum of all chemical processes of the body that modify endogenous or exogenous chemicals. Focus areas of toxicokinetics: Biotransformation
More informationMutational and phenotypical spectrum of phenylalanine hydroxylase deficiency in Denmark
Clin Genet 2016: 90: 247 251 Printed in Singapore. All rights reserved Short Report 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12692 Mutational and
More informationPrerequisites Amino acid synthesis and degradation pathways. Integration of amino acid metabolic pathways with carbohydrate metabolic pathways.
Case 30 Phenylketonuria Focus concept The characteristics of phenylalanine hydroxylase, the enzyme missing in persons afflicted with the genetic disorder phenylketonuria (PKU), are examined. Prerequisites
More informationNew Drug Evaluation: Pegvaliase-pqpz injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationIn vitro expression analysis of R68G and R68S mutations in phenylalanine hydroxylase gene
Vol. 47 No. 2/2000 365 369 QUARTERLY In vitro expression analysis of R68G and R68S mutations in phenylalanine hydroxylase gene Cezary ekanowski 1, Belen Perez 2, Lourdes R. Desviat 2, Wojciech Wiszniewski
More informationPKU, KUVAN, and You PKU treatment and support for adults and young adults
PKU, KUVAN, and You PKU treatment and support for adults and young adults An educational brochure brought to you by BioMarin Pharmaceutical Inc. Phe control it s a lifelong goal! Most young people with
More informationHuman inherited diseases
Human inherited diseases A genetic disorder that is caused by abnormality in an individual's DNA. Abnormalities can range from small mutation in a single gene to the addition or subtraction of a whole
More informationnumber Done by Corrected by Doctor
number 33 Done by Omar Sami Corrected by Waseem abu obeida Doctor Diala Too late for second guessing, too late to go back to sleep 1 P age Just try defying gravity This sheet will be divided to two parts,
More informationBEHAVIORAL ASSESMENT OF THE Pah enu2 MOUSE MODEL OF PHENYLKETONURIA PADMINI ASHOK KUMAR
BEHAVIORAL ASSESMENT OF THE Pah enu2 MOUSE MODEL OF PHENYLKETONURIA By PADMINI ASHOK KUMAR A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
More informationDisclosure. I have no disclosures to mention
Disclosure I have no disclosures to mention Liberalization of the Dietary Restrictions for PKU Patients: Large Neutral Amino Acids (LNAA) Supplementation in PKU Mice Dr. Eddy A. van der Zee, University
More informationRevision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kuvan) Reference Number: CP. PHAR.43 Effective Date: 02.01.10 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationStructural Studies on Phenylalanine Hydroxylase and Implications Toward Understanding and Treating Phenylketonuria
Structural Studies on Phenylalanine Hydroxylase and Implications Toward Understanding and Treating Phenylketonuria Heidi Erlandsen, DrSci; Marianne G. Patch, PhD; Alejandra Gamez, PhD; Mary Straub; and
More informationTetrahydrobiopterin responsiveness: results of the BH 4 loading test in 31 Spanish PKU patients and correlation with their genotype
Molecular Genetics and Metabolism 83 (2004) 157 162 www.elsevier.com/locate/ymgme Tetrahydrobiopterin responsiveness: results of the BH 4 loading test in 31 Spanish PKU patients and correlation with their
More informationTwo Siblings of Hyperphenylalaninemia: Suggestion to a Genetic Variant of Phenylketonuria
Tohoku J. exp Med., 1969, 100, 249-253 Two Siblings of Hyperphenylalaninemia: Suggestion to a Genetic Variant of Phenylketonuria Keiya Tada, Toshio Yoshida, Keiko Mochizuki, Tasuke Konno, Hiroshi Nakagawa,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Palynziq) Reference Number: CP.PHAR.140 Effective Date: 07.31.18 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationESPEN Congress Madrid 2018
ESPEN Congress Madrid 2018 Inborn Errors Of Metabolism Phenylketonuria A. Macdonald (UK) Approach to Dietary Management of PKU Conflicts of interest Anita MacDonald has received research funding and honoraria
More information44. Screening for Phenylketonuria
44. Screening for Phenylketonuria Burden of Suffering PKU is an inborn error of phenylalanine metabolism that occurs in 1 of every 12,000 births in North America. 1,2 In the absence of treatment during
More informationPHENYLKETONURIA. Debbie Galo
PHENYLKETONURIA Debbie Galo What it is PKU? 1934 Metabolic disorder (chromosome 12) Autosomal recessive Deficiency of enzyme Phenylalanine Hydroxylase (PAH) Cannot convert phenylalanine to tyrosine More
More informationSummary. Syndromic versus Etiologic. Definitions. Why does it matter? ASD=autism
Summary It is becoming clear that multiple genes with complex interactions underlie autism spectrum (ASD). A small subset of people with ASD, however, actually suffer from rare single-gene Important to
More informationNIH Public Access Author Manuscript Curr Dir Psychol Sci. Author manuscript; available in PMC 2010 February 1.
NIH Public Access Author Manuscript Published in final edited form as: Curr Dir Psychol Sci. 2009 February 1; 18(1): 48 52. doi:10.1111/j.1467-8721.2009.01604.x. Phenylketonuria in Children and Mothers:
More informationMetabolic Disorders. Chapter Thomson - Wadsworth
Metabolic Disorders Chapter 28 1 Metabolic Disorders Inborn errors of metabolism group of diseases that affect a wide variety of metabolic processes; defective processing or transport of amino acids, fatty
More informationPegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line
May 2016 Horizon Scanning Research & Intelligence Centre Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line LAY SUMMARY This briefing is based on information
More informationPKU PKU. Phenylketonuria TEMPLE. Information for families following Information for families after a positive newborn screening
PKU Phenylketonuria PKU Information for families following newborn a positive screening newborn screening Information for families after a positive newborn screening Information for families after a positive
More informationA model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients
Proc. Natl. Acad. Sci. USA Vol. 96, pp. 3160 3164, March 1999 Medical Sciences A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients SEYMOUR KAUFMAN* Laboratory of
More informationPKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ Australasian Society for Inborn Errors of Metabolism DESIGNED AND ADAPTED BY THE DIETITIANS GROUP PKU British
More informationTetrahydrobiopterin responsiveness in patients with phenylketonuria
Clinical Biochemistry 37 (2004) 1083 1090 Tetrahydrobiopterin responsiveness in patients with phenylketonuria Belén Pérez-Dueñas a, Maria Antonia Vilaseca b, *, Anna Mas c, Nilo Lambruschini d, Rafael
More informationUnderstanding Treatment Options for Phenylketonuria Webcast January 2011 Marie LeFrancois, Dt.P. John Mitchell, M.D. Anna Maiorino
Understanding Treatment Options for Phenylketonuria Webcast January 2011 Marie LeFrancois, Dt.P. John Mitchell, M.D. Anna Maiorino Please remember that the views expressed on Patient Power do not necessarily
More information- Aya Alomoush. - Talal Al-Zabin. - Belal Azab. 1 P a g e
24 - Aya Alomoush - Talal Al-Zabin - Belal Azab 1 P a g e 1) Features of autosomal dominant inheritance: A) Vertical transmission: direct transmission from grandparent to parent to child without skipping
More informationCommittee Approval Date: August 15, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru152 Topic: Kuvan, sapropterin Date of Origin: March 18, 2008 Committee Approval Date: August 15, 2014 Next Review Date: September 2015 Effective Date: October 1,
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 106 (2012) 264 268 Contents lists available at SciVerse ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Positive effect
More informationThe New England Journal of Medicine TETRAHYDROBIOPTERIN AS AN ALTERNATIVE TREATMENT FOR MILD PHENYLKETONURIA
TETRAHYDROBIOPTERIN AS AN ALTERNATIVE TREATMENT FOR MILD PHENYLKETONURIA ANIA C. MUNTAU, M.D., WULF RÖSCHINGER, M.D., MATTHIAS HABICH, HANS DEMMELMAIR, PH.D., BJÖRN HOFFMANN, CHRISTIAN P. SOMMERHOFF, M.D.,
More informationJana Novotná, Bruno Sopko. Department of the Medical Chemistry and Clinical Biochemistry The 2nd Faculty of Medicine, Charles Univ.
Amino acid metabolism II. Urea cycle Jana Novotná, Bruno Sopko Department of the Medical Chemistry and Clinical Biochemistry The 2nd Faculty of Medicine, Charles Univ. Nitrogen balance Tissue proteins
More informationTEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP British Inherited Metabolic Diseases Group BASED ON THE ORIGINAL TEMPLE WRITTEN BY BURGARD AND WENDEL PKU Information for
More informationCell encapsulation as a potential non-dietary therapy for maternal phenylketonuria
University of Iowa Iowa Research Online Theses and Dissertations Summer 2012 Cell encapsulation as a potential non-dietary therapy for maternal phenylketonuria Anita Jesaro Xavier University of Iowa Copyright
More informationHyperphenylalaninemia (HPA) has been called the epitome
GENETEST REVIEW Genetics in Medicine John J. Mitchell, MD 1,2,3, Yannis J. Trakadis, MD 1, and Charles R. Scriver, MD 1,2 TABLE OF CONTENTS Classification schemes...698 Clinical description...698 Untreated
More informationPAH Mutation Analysis Consortium Database: a database for disease-producing and other allelic variation at the human PAH locus
1996 Oxford University Press Nucleic Acids Research, 1996, Vol. 24, No. 1 127 131 PAH Mutation Analysis Consortium Database: a database for disease-producing and other allelic variation at the human PAH
More informationScreening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force
Screening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force Prepared by: Iris Mabry-Hernandez, MD, MPH Tracy Wolff, MD, MPH Kathy Green, MD, MPH Corresponding Author:
More informationSapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four
The Turkish Journal of Pediatrics 2015; 57: 213-218 Original Sapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four Özlem Ünal 1, Hülya Gökmen-Özel 2, Turgay Coşkun
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 99 (2010) S90 S95 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Future treatment strategies
More informationFor topical use only. Not for oral, ophthalmic, or intravaginal use.
DESOXIMETASONE Ointment USP, 0.25% For topical use only. Not for oral, ophthalmic, or intravaginal use. Rx only DESCRIPTION Desoximetasone ointment USP, 0.25% contains the active synthetic corticosteroid
More informationNEUROCOGNITIVE, OUTCOMES IN PKU: IT S TIME TO RAISE THE BAR
NEUROCOGNITIVE, OUTCOMES IN : IT S TIME TO RAISE THE BAR KEY POINTS 1. High Phenylalanine (Phe) levels harm the brain.. Traditional therapies do not completely protect individuals with. 3. New approaches
More informationAmino Acid Oxidation and the Urea Cycle
Amino Acid Oxidation and the Urea Cycle Amino Acids: Final class of biomolecules whose oxidation contributes significantly to the generation of energy Undergo oxidation in three metabolic circumstances
More informationBiochemistry: A Short Course
Tymoczko Berg Stryer Biochemistry: A Short Course Second Edition CHAPTER 30 Amino Acid Degradation and the Urea Cycle 2013 W. H. Freeman and Company Chapter 30 Outline Amino acids are obtained from the
More informationUniversity of Zurich. Zurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2011 The interplay between genotype, metabolic state and cofactor treatment governs
More informationBAHAN AJAR IV Phenylketonurias (Phenylalanine Hydroxylase Deficiency) Nama Mata Kuliah/Bobot SKS : Sistem Neuropsikiatri / 8 SKS
BAHAN AJAR IV Phenylketonurias (Phenylalanine Hydroxylase Deficiency) Nama Mata Kuliah/Bobot SKS : Sistem Neuropsikiatri / 8 SKS Standar Kompetensi : area kompetensi 5: landasan ilmiah kedokteran Kompetensi
More informationAmino acid Catabolism
Enzymatic digestion of dietary proteins in gastrointestinal-tract. Amino acid Catabolism Amino acids: 1. There are 20 different amino acid, they are monomeric constituents of proteins 2. They act as precursors
More informationOriginal Articles. Pitfalls in the Management of Phenylketonuria in China LL YANG, HQ MAO, WF ZHANG, ZY ZHAO, RL YANG, XL ZHOU, XL HUANG, XW HUANG
HK J Paediatr (new series) 2012;17:143-147 Original Articles Pitfalls in the Management of Phenylketonuria in China LL YANG, HQ MAO, WF ZHANG, ZY ZHAO, RL YANG, XL ZHOU, XL HUANG, XW HUANG Abstract Key
More informationPhenylketonuria: Optimizing Therapeutic Efficacy
Phenylketonuria: Optimizing Therapeutic Efficacy Expanded Reference List Abadie V, Berthelot J, Feillet F, et al. Management of phenylketonuria and hyperphenylalaninemia: the French guidelines. Arch Pediatr.
More informationS2 Protein augmentation therapies for inherited disorders 1
Disease category Disorder S2 Protein augmentation therapies for inherited 1 Augmented protein 2 Source of therapeutic protein / peptide Outcome References 3 Membrane transport Coagulation Cystic fibrosis
More informationAmerican Journal of Human Genetics. American Journal of Hypertension. American Journal of Neuroradiology
A) Acta Neurochir AJNR Am J Neuroradiol Am Coll Rheumatol Am J Cardiol Am J Hum Genet Am J Hypertens Am J Neuroradiol AJNR Am J Physiol Am J Physiol Gastrointest Liver Physiol Am J Physiol Heart Circ physiol
More informationPEPTIDES and PROTEINS
PEPTIDES and PROTEINS - Learned basic chemistry of amino acids structure and charges - Chemical nature/charges of amino acids is CRUCIAL to the structure and function of proteins - Amino acids can assemble
More informationTHBA Platform - Bile acid imbalance
- Bile acid imbalance Bile acids play an important role in maintaining human health by means of signaling molecules in the regulation of bile formation, liver function and metabolism. The detergent effect
More information2015 PKU Patient Survey Results. National PKU Alliance PO Box 501, Tomahawk, WI
2015 PKU Patient Survey Results National PKU Alliance PO Box 501, Tomahawk, WI 54487 www.npkua.org www.adultswithpku.org The NPKUA Patient Survey demonstrates that strict dietary therapy and treatment
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: van Spronsen FJ, van Wegberg AMJ, Ahring K,
More informationPhenylketonuria in Iranian population: a study in institutions for mentally retarded in Isfahan
Mutation Research 526 (2003) 45 52 Phenylketonuria in Iranian population: a study in institutions for mentally retarded in Isfahan Sadeq Vallian, Elham Barahimi 1, Hasan Moeini Department of Biology, Faculty
More informationGenetics Unit Exam. Number of progeny with following phenotype Experiment Red White #1: Fish 2 (red) with Fish 3 (red) 100 0
Genetics Unit Exam Question You are working with an ornamental fish that shows two color phenotypes, red or white. The color is controlled by a single gene. These fish are hermaphrodites meaning they can
More informationHA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up Dr. Josephine Chong Clinical Professional Consultant Centre of Inborn Errors
More informationNutritional need versus optimal intake. Hemilä, Harri O.
https://helda.helsinki.fi Nutritional need versus optimal intake Hemilä, Harri O 1984 Hemilä, H O 1984, ' Nutritional need versus optimal intake ' Medical Hypotheses, vol 14, no. 2, pp. 135-139. DOI: 10.1016/0306-9877(84)90051-3
More informationBIOCHEMISTRY Protein Metabolism
BIOCHEMISTRY Protein Metabolism BIOB111 CHEMISTRY & BIOCHEMISTRY Session 25 Session Plan Digestion & Absorption of Proteins Amino Acid Utilization Amino Acid Degradation Transamination Oxidative Deamination
More informationUPDATE ON UREA CYCLE DISORDERS TREATMENT
UPDATE ON UREA CYCLE DISORDERS TREATMENT George A. Diaz, MD, PhD Program for Inherited Metabolic Diseases Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai Disclosure
More informationNew developments in Urea Cycle Disorders and its impact on patients
New developments in Urea Cycle Disorders and its impact on patients Johannes Häberle University Children s Hospital Zurich, Division of Metabolism 16 June 2015 SFEIM 2015, Lille, France The urea cycle
More informationPROTEIN METABOLISM: SPECIFIC WAYS OF AMINO ACIDS CATABOLISM AND SYNTHESIS
PROTEIN METABOLISM: SPECIFIC WAYS OF AMINO ACIDS CATABOLISM AND SYNTHESIS SPECIFIC WAYS OF AMINO ACID CATABOLISM After removing of amino group the carbon skeletons of amino acids are transformed into metabolic
More informationFIRST BIOCHEMISTRY EXAM Tuesday 25/10/ MCQs. Location : 102, 105, 106, 301, 302
FIRST BIOCHEMISTRY EXAM Tuesday 25/10/2016 10-11 40 MCQs. Location : 102, 105, 106, 301, 302 The Behavior of Proteins: Enzymes, Mechanisms, and Control General theory of enzyme action, by Leonor Michaelis
More informationNutritional Management of Inborn Errors of Metabolism. Kay Davis, RD, CSP Esther Berenhaut, RD, CSP, CSR Aug 28, 2017
Nutritional Management of Inborn Errors of Metabolism Kay Davis, RD, CSP Esther Berenhaut, RD, CSP, CSR Aug 28, 2017 OBJECTIVES Brief overview of newborn screening of metabolic disorders, inheritance patterns.
More information11: Pathways. Reminders:
11: Pathways Reminders: 1. Due in lab NEXT week: a. Pre- Lab 05 b. Amylase lab report 2. Exam 4 Monday (see SPOC for details) Last names A F Ryan Lounge M- 3-721 Last names G - Z here (1 pt for right room)
More informationBY: RASAQ NURUDEEN OLAJIDE
BY: RASAQ NURUDEEN OLAJIDE AROMATIC AMINO ACID DEGRADATION The aromatic amino acids are those containing aromatic or benzene ring in their side chains Examples include phenylalanine, tyrosine and tryptophan
More information